Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 18/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | GIPR | P48546 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.44 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.44 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.44 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.44 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.44 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.44 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.44 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.44 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3106760 | 0.92 | SPHK2 (0.46) | GCGRGIPR | |
| SCHEMBL3090570 | 0.82 | GCGR (0.56) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2667055 | 0.79 | FFAR1 (0.54) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL3104908 | 0.78 | PPARD (0.46) | PTGER4 | |
| SCHEMBL3107388 | 0.78 | PPARD (0.58) | PTGER4 | |
| SCHEMBL3101002 | 0.78 | PPARD (0.43) | GCGRPTGER4 | |
| SCHEMBL14039406 | 0.78 | FFAR1 (0.52) | GCGRPTGER4GIPRCYP3A4CYP2C8 | |
| SCHEMBL3106672 | 0.77 | GCGR (0.49) | GCGRGIPR | |
| SCHEMBL2667053 | 0.77 | GCGR (0.54) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2667025 | 0.76 | GCGR (0.57) | GCGRGIPRCYP3A4CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210876-B1 | HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2210876-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | GLP1R, GPR119, GCGR | GCGR 3/4885PTGER4 1524/4885GIPR 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.